Hydroxyurea API

Name	Hydroxyurea
Chinese name	羟基脲
Cas Number	127-07-1
Source	Europe
Qualifications	USDMF/CEP/-/-/-

Hydroxyurea has a long history of clinical application in antiviral and antitumor aspects, and it is still the first-line drug for many diseases, including the treatment of polycythemia vera, essential thrombocythemia, chronic myeloid leukemia and primary bone marrow fibers Myeloproliferative diseases such as chemistry. Hydroxyurea is a nucleoside diphosphate reductase inhibitor that prevents the reduction of nucleotides to deoxynucleotides, interferes with the biosynthesis of purine and pyrimidine bases, thereby selectively hindering DNA synthesis. Research data for the treatment of sickle cell anemia shows that compared with pre-treatment levels, the use of hydroxyurea and SCA patients reduce pain by an average of 55%, infections by 38%, malaria by 51%, blood transfusions by 67%, and mortality by 70%. related. Another study has explored the application of a pharmaceutical composition containing hydroxyurea in the preparation of drugs for the prevention and/or treatment of atherosclerosis, and its effect is far superior to the current clinical treatment regimens (such as oral aspirin and hydrogen chloride A combination of pidogrel or atorvastatin calcium alone). In recent years, with the continuous expansion of the scope of clinical applications, many new clinical uses of hydroxyurea have gradually been discovered, in sickle cell anemia, β-thalassemia, psoriasis, polycythemia vera, and essential thrombocythemia , AIDS treatment has achieved good results.

Hot Tags: hydroxyurea api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Canagliflozin API, Apremilast API, Deoxycholic Acid API, Rasagiline Mesylate API, Pabxilib API, Teriflunomide API

• Previous: Cytarabine API
• Next: Pilocarpine Hydrochloride API